IL5 and Alzheimer disease: In vivo studies conducted using an Ovalbumin-induced AD animal model revealed that the treated group had markedly lower levels of INF-γ, IL-4, and IL-5; reduced TEWL; and decreased OVA-IgE serum levels, alongside improvements in skin integrity and reduced skin thickness.